I get all my info from 2nd or 3rd hand voices. Have heard the CU dosage was very much higher than trial. I believe that to be true but have nothing other than sources are solid people to make me believe same. Same thing with FDA limiting our trial dosage.

I believe the possibility because B has proven the ability in prior trials to perform as expected due to in vitro testing. The SI of 426 was no fluke. So what other than the above could one attest the inability for B to shine in the TL objective?

We will see when secondary objective (I worry low dosage may hinder these showing strongly positive) results are put out the end of the month and the real proof of the pudding is when the Compassionate Use data is released around the same time. Those should show some strong positives for B across the board IMO. I also have to believe since Cu patients weren't in a blind test that Leo was informed continuously how patients were doing so he already knows the results were positive.

Hope the above holds true as they are our main avenues for B moving forward for Covid IMO - or at least the factors that would cause some BP to help IPIX move B forward by cutting a deal with us.

I am kind of the loose cannon on the board so take everything I say with a grain of salt. I say what I believe and that hasn't always proven to be the yellow brick road I thought it was when I made my predictions.